Abstract:[Objective] To explore the significance of tranexamic acid (TXA) used in total hip arthroplasty (THA) with HIV infection. [Methods] A total of 59 male patients who underwent primary unilateral THA for femoral head necrosis complicated with HIV infection from November 2010 to September 2020 were enrolled into this study. Of them, 31 patients had TXA used, while the remaining 28 patients had no TXA applied. The documents regarding to perioperative clinical consequences, laboratory test and color ultrasound examination were compared between the two groups. [Results] Although there was no significant difference in operation time and incision length be- tween the two groups (P>0.05) , the TXA group proved significantly superior to the non-TXA group in terms of blood loss, including total blood loss, dominant blood loss, recessive blood loss, blood transfusion rate, incision healing grade, hospital stay and the time to resume full weight-bearing activity (P<0.05) . Ultrasonographically, there was no significant difference in intermuscular vein thrombosis found between the two groups before and 3 days after operation (P>0.05) . In terms of laboratory test, Hb and Hct in the TXA group were significantly high- er than those in the non-TXA group 1 and 3 days postoperatively (P<0.05) , in addition, the CRP at 3 and 7 days after operation, ESR and DD 7 days postoperatively in TXA group were significantly lower than those in non-TXA group (P<0.05) . [Conclusion] TXA is a safe and effective adjunctive drug used for THA of HIV patients, which can reduce perioperative blood loss and incision complications without in- creasing the incidence of venous thrombosis.